BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tom Yeung here with your Sunday Digest.  Last month, I wrote about ...

We recognize and have recognized for some time that Alzheimer’s disease is a public health crisis,” said Meggie Gaskins.

Donanemab, the newly FDA-approved Alzheimer’s drug, offers monthly infusion treatment that slows early cognitive decline by ...

Biogen Inc (BIIB) reports a 6% revenue increase driven by new product launches, despite facing competitive pressures in its MS franchise.

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Discover key insights from Biogen's Q1 2025 earnings call, highlighting LEQEMBI's growth, product launches, and a strong pipeline driving ...